Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.69 |
| ▸ | PGR | P06401 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | IKBKB | O14920 | 1/20 | 0.69 |
| ▸ | CHUK | O15111 | 1/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.69 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL28086533 | 0.96 | HIF1A (0.66) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Triamcinolone SCHEMBL593313 | 0.95 | HIF1A (0.68) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Hydrocortisone Phosphoric Acid SCHEMBL8190634 | 0.92 | HIF1A (0.66) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL3309785 | 0.91 | NR3C1 (0.73) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7070539 | 0.91 | NR3C1 (0.73) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL4586353 | 0.90 | HIF1A (0.56) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL3135309 | 0.89 | NR3C1 (0.68) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3224067 | 0.89 | NR3C1 (0.68) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Hydrocortisone SCHEMBL8190636 | 0.89 | NR3C1 (0.57) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Tixocortol Pivalate SCHEMBL4455114 | 0.88 | HIF1A (0.60) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021087179-A1 | PERIODONTAL MICROPATCH AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-06 | — | — | WO | claimed |
| US-20200093887-A1 | OPHTHALMIC TREATMENT COMPOSITION AND VEHICLE FOR DELIVERY OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTIC AGENTS | GAVARIS PAUL (US) | 2020-03-26 | — | — | US | claimed |
| WO-2018038966-A1 | PHARMACEUTICAL COMPOSITIONS FOR INDUCING PHENOTYPIC REVERSION OF A CELL AND REGENERATION OF COMPROMISED TISSUE | PAZ GARCIA JUAN (MX) | 2018-03-01 | — | — | WO | claimed |
| US-20160354446-A1 | Formulation for Regeneration of Bone, Cartilage, Teeth, and Periodontium and Treatment of Tumors and Cysts | REGEN THERAPIES, INC. | 2016-12-08 | — | — | US | claimed |
| US-20150335660-A1 | Formulation for Regeneration of Bone, Cartilage, Teeth, and Periodontium and Treatment of Tumors and Cysts | REGEN THERAPIES, INC. | 2015-11-26 | — | — | US | claimed |
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| EP-1592387-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1877004-A2 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | ABBOTT LABORATORIES (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1871367-A2 | COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES | Xanthus Pharmaceuticals, Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2007111925-A2 | ZOTAROLIMUS-CONTAINING DRUG DELIVERY SYSTEMS FOR IMPLANTATION INTO A BODY LUMEN OF A SUBJECT | ABBOTT LABORATORIES (US) | 2007-10-04 | — | — | WO | claimed |
| WO-2007032777-A2 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | ABBOTT LABORATORIES (US) | 2007-03-22 | — | — | WO | claimed |
| US-20060198867-A1 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | ABBOTT LABORATORIES, INC. (US) | 2006-09-07 | — | — | US | claimed |
| US-20060189546-A1 | Compounds for treating autoimmune and demyelinating diseases | XANTHUS PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | claimed |
| WO-2006081431-A2 | COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES | XANTHUS PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
| EP-1592386-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| EP-1592387-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN MA INC. | 2005-09-29 | — | — | US | claimed |
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-03-31 | — | — | US | claimed |
| WO-2004066932-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| WO-2004066931-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198867-A1 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | RICTOR, VEGFA, MTOR | NR3C1 1901/4885HIF1A 1915/4885CYP3A4 3121/4885 |
| US-20050215565-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | NR3C1 3908/4885HIF1A 2729/4885CYP3A4 4881/4885 |
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | MAG, PMP22, GAP43 | NR3C1 3908/4885HIF1A 2729/4885CYP3A4 4881/4885 |
| US-20060189546-A1 | Compounds for treating autoimmune and demyelinating diseases | PMP22, MAG, MYT1 | NR3C1 885/4885HIF1A 3899/4885CYP3A4 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.